Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1641 1644
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18242868 | FACTOR X BINDERS ENHANCING FX ACTIVATION | Final Rejection | Novo Nordisk A/S |
| 18249991 | NATURAL KILLER CELLS WITH ENHANCED ACTIVITY | Non-Final OA | The Regents of the University of California |
| 18048386 | THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS | Non-Final OA | The Regents of the University of California |
| 17868422 | SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION | Final Rejection | The Regents of the University of Michigan |
| 18247198 | METHODS FOR REDUCING HOST CELL PROTEIN CONTENT IN ANTIBODY PURIFICATION PROCESSES AND ANTIBODY COMPOSITIONS HAVING REDUCED HOST CELL PROTEIN CONTENT | Non-Final OA | Eli Lilly and Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy